Two-year extension of a one-year, multicenter, randomized, partially-blinded study of the safety and efficacy of FTY720 [fingolimod] combined with corticosteroids and full or reduced-dose cyclosporin, USP [modified] (Novartis brand) in de novo adult renal transplant recipients.

Trial Profile

Two-year extension of a one-year, multicenter, randomized, partially-blinded study of the safety and efficacy of FTY720 [fingolimod] combined with corticosteroids and full or reduced-dose cyclosporin, USP [modified] (Novartis brand) in de novo adult renal transplant recipients.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 14 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top